Application of Computational Biology and Artificial Intelligence in Drug Design
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Traditional drug design requires a great amount of research time and developmental expense. Booming computational approaches, including computational biology, computer-aided drug design, and artificial intelligence, have the potential to expedite the efficiency of drug discovery by minimizing the time and financial cost. In recent years, computational approaches are being widely used to improve the efficacy and effectiveness of drug discovery and pipeline, leading to the approval of plenty of new drugs for marketing. The present review emphasizes on the applications of these indispensable computational approaches in aiding target identification, lead discovery, and lead optimization. Some challenges of using these approaches for drug design are also discussed. Moreover, we propose a methodology for integrating various computational techniques into new drug discovery and design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057 · cited 2×
“The most frequently used molecular docking tools include Autodock [190], AutoDock Vina [191], CDOCKER [192], GLIDE [193], DOCK6 [194], GOLD [195], FLEXX [196], and SwissDock [197].”
BackgroundMethodDrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
Varadi, M., Anyango, S., Deshpande, M., Nair, S., Natassia, C., Yordanova, G., Yuan, D., Stroe, O., Wood, G., Laydon, A., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1061 · Cited by 7,850
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
PubChem Substance and Compound databases
Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., Shoemaker, B. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv951 · Cited by 5,436 · cited 1×
“…purchasable compounds in ready-to-dock) [89,177,178], MCULE (122 million synthetic compounds) [179], PubChem (112 million bioactive compounds) [180,181], DrugBank (14,528 approved drug molecules or experimental drugs) [182,183], ChEMBL (approximately 2.2 million bioactive molecules with…”
BackgroundInfluentialChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382 · cited 1×
“…(112 million bioactive compounds) [180,181], DrugBank (14,528 approved drug molecules or experimental drugs) [182,183], ChEMBL (approximately 2.2 million bioactive molecules with drug-like properties) [184,185], and ChemDB (approximately 5 million commercially available small molecules) [186].”
BackgroundInfluentialZINC − A Free Database of Commercially Available Compounds for Virtual Screening
Irwin, J. J., & Shoichet, B. K. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049714+ · Cited by 4,058 · cited 1×
“…such as the REAL library of Enamine (1.4 billion make-on-demand compounds) [176], ZINC (750 million purchasable compounds in ready-to-dock) [89,177,178], MCULE (122 million synthetic compounds) [179], PubChem (112 million bioactive compounds) [180,181], DrugBank (14,528 approved drug…”
BackgroundInfluentialPubChem in 2021: new data content and improved web interfaces
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa971 · Cited by 3,953 · cited 1×
“PubChem [233,264,266] Public chemical database at the National Library of Medicine (NLM) collects chemical information from different data sources.”
BackgroundMolecular Docking: A Powerful Approach for Structure-Based Drug Discovery
Meng, X.-Y., Zhang, H.-X., Mezei, M., & Cui, M. (2011) · Current Computer Aided-Drug Design · doi:10.2174/157340911795677602 · Cited by 3,771
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359 · cited 1×
“Drug discovery is a lengthy, expensive, and complicated process that spans years and costs millions of dollars [1,2].”
BackgroundZINC 15 – Ligand Discovery for Everyone
Sterling, T., & Irwin, J. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00559 · Cited by 3,224
Supervised Sequence Labelling with Recurrent Neural Networks
Graves, A. (2012) · Studies in Computational Intelligence · doi:10.1007/978-3-642-24797-2 · Cited by 3,120
Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules
Gómez-Bombarelli, R., Wei, J. N., Duvenaud, D., Hernández-Lobato, J. M., Sánchez-Lengeling, B., Sheberla, D., Aguilera-Iparraguirre, J., Hirzel, T. D., Adams, R. P., & Aspuru-Guzik, A. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00572 · Cited by 3,106
QSAR Modeling: Where have you been? Where are you going to?
Cherkasov, A., Muratov, E. N., Fourches, D., Varnek, A., Baskin, I. I., Cronin, M., Dearden, J., Gramatica, P., Martin, Y. C., Todeschini, R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4004285 · Cited by 2,164
SwissDock, a protein-small molecule docking web service based on EADock DSS
Grosdidier, A., Zoete, V., & Michielin, O. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr366 · Cited by 1,950
The rise of deep learning in drug discovery
Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.039 · Cited by 1,770
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573
Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks
Segler, M. H. S., Kogej, T., Tyrchan, C., & Waller, M. P. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00512 · Cited by 1,537
Enumeration of 166 Billion Organic Small Molecules in the Chemical Universe Database GDB-17
Ruddigkeit, L., van Deursen, R., Blum, L. C., & Reymond, J.-L. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300415d · Cited by 1,505 · cited 1×
“…from GDB-11, it enumerates in a similar manner small organic molecules containing up to 13 atoms of C, N, O, S, and Cl. 970 million GDB-17 [231,232,254,273] Chemical universe database covers drugs and typical for lead compounds for molecules with up to 17 atoms of C, N, O, S, and halogens.”
BackgroundRethinking drug design in the artificial intelligence era
Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., Fisher, J., Jansen, J. M., Duca, J. S., Rush, T. S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0050-3 · Cited by 894 · cited 2×
“Statistical machine learning methods and deep learning methods help to build the classification or regression model that can predict molecular properties [263,309].”
BackgroundMethodFrom machine learning to deep learning: progress in machine intelligence for rational drug discovery
Zhang, L., Tan, J., Han, D., & Zhu, H. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.08.010 · Cited by 760 · cited 2×
“The approaches also contribute to the generation of novel compounds [32,34].”
BackgroundMethodDeep Learning in Drug Discovery
Gawehn, E., Hiss, J. A., & Schneider, G. (2016) · Molecular Informatics · doi:10.1002/minf.201501008 · Cited by 723
Machine Learning in Computer-Aided Synthesis Planning
Coley, C. W., Green, W. H., & Jensen, K. F. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00087 · Cited by 704
MolGAN: An implicit generative model for small molecular graphs
De Cao, N., & Kipf, T. (2018) · arXiv · doi:10.48550/arxiv.1805.11973 · Cited by 442
The transformational role of GPU computing and deep learning in drug discovery
Pandey, M., Fernandez, M., Gentile, F., Isayev, O., Tropsha, A., Stern, A. C., & Cherkasov, A. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00463-x · Cited by 255
The Free Energy Landscape of Small Molecule Unbinding
Huang, D., & Caflisch, A. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002002 · Cited by 116 · cited 1×
“Moreover, MD simulations can provide the thermodynamics and free energy profiles of target–ligand interactions [11].”
BackgroundRELATION: A Deep Generative Model for Structure-Based De Novo Drug Design
Wang, M., Hsieh, C.-Y., Wang, J., Wang, D., Weng, G., Shen, C., Yao, X., Bing, Z., Li, H., Cao, D., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00732 · Cited by 99 · cited 2×
“…distribution by applying the variational autoencoder architecture, which consists of a 3D convolutional encoder, a LSTM-based captioning decoder and a bidirectional transfer learning module in order to transfer the features of protein-ligand complexes to latent space, for molecule generation [251].”
MethodUni-Mol: A Universal 3D Molecular Representation Learning Framework
Zhou, G., Gao, Z., Ding, Q., Zheng, H., Xu, H., Wei, Z., Zhang, L., & Ke, G. (2022) · doi:10.26434/chemrxiv-2022-jjm0j · Cited by 81
Thomas, M., Smith, R. T., O’Boyle, N. M., de Graaf, C., & Bender, A. (2021) · Journal of Cheminformatics · doi:10.1186/s13321-021-00516-0 · Cited by 78
Computational complexity in electronic structure
Whitfield, J. D., Love, P. J., & Aspuru-Guzik, A. (2013) · Phys. Chem. Chem. Phys. · doi:10.1039/c2cp42695a · Cited by 71 · cited 2×
“M Fock matrix at O( M 3 ) cost ( M represents the number of basis functions) [146] .”
BackgroundOn-the-fly QM/MM docking with attracting cavities.
Chaskar, P., Zoete, V., & Röhrig, U. F. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00406 · Cited by 46
Can Generative-Model-Based Drug Design Become a New Normal in Drug Discovery?
Chen, H. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02042 · Cited by 21
Research works printed but not linked: 295
- Song, 2009, Recent advances in computer-aided drug design, Brief. Bioinform., 10, 579, 10.1093/bib/bbp023 · DOI · Paper page
- Kalyan, 2018, Pharmaceutical Medicine and Translational Clinical Research, Curr. Sci., 115, 1403
- Sabe, 2021, Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review, Eur. J. Med. Chem., 224, 113705, 10.1016/j.ejmech.2021.113705 · DOI · Paper page
- Gurung, 2021, An Updated Review of Computer-Aided Drug Design and Its Application to COVID-19, BioMed Res. Int., 2021, 8853056, 10.1155/2021/8853056 · DOI · Paper page
- Zhong, 2018, Artificial intelligence in drug design, Sci. China Life Sci., 61, 1191, 10.1007/s11427-018-9342-2 · DOI · Paper page
- Hou, 2004, Recent development and application of virtual screening in drug discovery: An overview, Curr. Pharm. Des., 10, 1011, 10.2174/1381612043452721 · DOI · Paper page
- Hill, R.G., and Richards, D. (2021). Drug Discovery and Development E-Book: Technology in Transition, Elsevier Health Sciences.
- Durrant, J.D., and McCammon, J.A. (2011). Molecular dynamics simulations and drug discovery. BMC Biol., 9. · DOI · Paper page
- Zhao, 2015, Molecular dynamics in drug design, Eur. J. Med. Chem., 91, 4, 10.1016/j.ejmech.2014.08.004 · DOI · Paper page
- Honarparvar, 2014, Integrated approach to structure-based enzymatic drug design: Molecular modeling, spectroscopy, and experimental bioactivity, Chem. Rev., 114, 493, 10.1021/cr300314q · DOI · Paper page
- Labanowski, J.K., and Andzelm, J.W. (2012). Density Functional Methods in Chemistry, Springer.
- Hafner, 2008, Ab-initio simulations of materials using VASP: Density-functional theory and beyond, J. Comput. Chem., 29, 2044, 10.1002/jcc.21057 · DOI · Paper page
- Chivian, 2003, Ab initio methods, Meth. Biochem. Anal., 44, 547, 10.1002/0471721204.ch27 · DOI
- Sebastiani, 2003, Advances in Density-Functional-Based Modeling Techniques-Recent Extensions of the Car-Parrinello Approach, Meth. Princ. Med. Chem., 17, 5
- Veselovsky, 2003, Strategy of computer-aided drug design, Curr. Drug Targets-Infect. Disord., 3, 33, 10.2174/1568005033342145 · doi:10.2174/1568005033342145
- Surabhi, 2018, Computer aided drug design: An overview, J. Drug Deliv. Ther., 8, 504, 10.22270/jddt.v8i5.1894 · DOI · Paper page
- Kore, 2012, Computer-aided drug design: An innovative tool for modeling, Open J. Med. Chem., 2, 139
- Baig, 2016, Computer aided drug design: Success and limitations, Curr. Pharm. Des., 22, 572, 10.2174/1381612822666151125000550 · DOI · Paper page
- Yu, W., and MacKerell, A.D. (2017). Computer-aided drug design methods. Antibiotics, Springer. · DOI · Paper page
- Lyne, 2002, Structure-based virtual screening: An overview, Drug Discov. Today, 7, 1047, 10.1016/S1359-6446(02)02483-2 · DOI · Paper page
- Lionta, 2014, Structure-based virtual screening for drug discovery: Principles, applications and recent advances, Curr. Top. Med. Chem., 14, 1923, 10.2174/1568026614666140929124445 · DOI · Paper page
- 2018, A review of ligand-based virtual screening web tools and screening algorithms in large molecular databases in the age of big data, Future Med. Chem., 10, 2641, 10.4155/fmc-2018-0076 · DOI
- Lavecchia, 2013, Virtual screening strategies in drug discovery: A critical review, Curr. Med. Chem., 20, 2839, 10.2174/09298673113209990001 · DOI · Paper page
- Sohraby, F., Bagheri, M., and Aryapour, H. (2019). Performing an in silico repurposing of existing drugs by combining virtual screening and molecular dynamics simulation. Computational Methods for Drug Repurposing, Springer. · DOI
- Issa, 2013, Drug repurposing a reality: From computers to the clinic, Expert Rev. Clin. Pharmacol., 6, 95, 10.1586/ecp.12.79 · DOI
- Duch, 2007, Artificial intelligence approaches for rational drug design and discovery, Curr. Pharm. Des., 13, 1497, 10.2174/138161207780765954 · DOI · Paper page
- Gertrudes, 2012, Machine learning techniques and drug design, Curr. Med. Chem., 19, 4289, 10.2174/092986712802884259 · DOI · Paper page
- Lima, 2016, Use of machine learning approaches for novel drug discovery, Expert Opin. Drug Discov., 11, 225, 10.1517/17460441.2016.1146250 · DOI · Paper page
- Klambauer, 2019, Machine Learning in Drug Discovery, J. Chem. Inf. Model., 59, 945, 10.1021/acs.jcim.9b00136 · DOI · Paper page
- Carpenter, 2018, Machine learning-based virtual screening and its applications to Alzheimer’s drug discovery: A review, Curr. Pharm. Des., 24, 3347, 10.2174/1381612824666180607124038 · DOI · Paper page
- Mendolia, I., Contino, S., Perricone, U., Ardizzone, E., and Pirrone, R. (2020). Convolutional architectures for virtual screening. BMC Bioinform., 21. · DOI
- Bohr, H. (2020). Drug discovery and molecular modeling using artificial intelligence. Artificial Intelligence in Healthcare, Elsevier. · DOI
- Gimeno, A., Ojeda-Montes, M.J., Tomás-Hernández, S., Cereto-Massagué, A., Beltrán-Debón, R., Mulero, M., Pujadas, G., and Garcia-Vallvé, S. (2019). The light and dark sides of virtual screening: What is there to know?. Int. J. Mol. Sci., 20. · DOI · Paper page
- Liu, 2018, Molecular dynamics simulations and novel drug discovery, Expert Opin. Drug Discov., 13, 23, 10.1080/17460441.2018.1403419 · DOI · Paper page
- Yan, 2022, The advanced development of molecular targeted therapy for hepatocellular carcinoma, Cancer Biol. Med., 19, 802, 10.20892/j.issn.2095-3941.2021.0661 · DOI
- Boomsma, 2016, Bioinformatics analysis identifies several intrinsically disordered human E3 ubiquitin-protein ligases, PeerJ, 4, e1725, 10.7717/peerj.1725 · DOI
- Xia, 2017, Bioinformatics and drug discovery, Curr. Top. Med. Chem., 17, 1709, 10.2174/1568026617666161116143440 · DOI · Paper page
- Huang, 2021, AURKB, CHEK1 and NEK2 as the Potential Target Proteins of Scutellaria barbata on Hepatocellular Carcinoma: An Integrated Bioinformatics Analysis, Int. J. Gen. Med., 14, 3295, 10.2147/IJGM.S318077 · doi:10.2147/ijgm.s318077
- Gordon, 2020, Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms, Science, 370, eabe9403, 10.1126/science.abe9403 · DOI · Paper page
- Chen, 2020, Target identification of natural medicine with chemical proteomics approach: Probe synthesis, target fishing and protein identification, Signal Transduct. Target. Ther., 5, 72, 10.1038/s41392-020-0186-y · DOI · Paper page
- Guo, 2012, Influence of the pathogenic mutations T188K/R/A on the structural stability and misfolding of human prion protein: Insight from molecular dynamics simulations, Biochim. Biophys. Acta Gen. Subj., 1820, 116, 10.1016/j.bbagen.2011.11.013 · DOI
- Hansson, 2002, Molecular dynamics simulations, Curr. Opin. Struct. Biol., 12, 190, 10.1016/S0959-440X(02)00308-1 · DOI · Paper page
- Hasan, 2020, Design and synthesis of graphene oxide-based glass substrate and its antimicrobial activity against MDR Bacterial Pathogens, J. Mech. Eng. Res. Dev., 43, 11
- Barone, 2004, Computation of protein pK’s values by an integrated density functional theory/polarizable continuum model approach, Theor. Chem. Acc., 111, 237, 10.1007/s00214-003-0541-4 · doi:10.1007/s00214-003-0541-4
- Souza, 2019, An allosteric pathway in copper, zinc superoxide dismutase unravels the molecular mechanism of the G93A amyotrophic lateral sclerosis-linked mutation, J. Phys. Chem. Lett., 10, 7740, 10.1021/acs.jpclett.9b02868 · DOI · Paper page
- Moreira, 2016, Reaction mechanism of Mycobacterium Tuberculosis glutamine synthetase using quantum mechanics/molecular mechanics calculations, Chem. A Eur. J., 22, 9218, 10.1002/chem.201600305 · doi:10.1002/chem.201600305
- Peters, 2006, Quantum mechanics in structure-based drug design, Curr. Opin. Drug Discov. Dev., 9, 370
- Barman, T.K., Hazarika, A.K., Kalita, U., Dhar, R., Borah, L., Chetri, S., and Ghosh, S.S. (2022). Epidemiology of Anti-HIV Drug Resistance: Quantum Mechanics (Qm) and Molecular Mechanics (MM) Studies into the Binding of 6-Aminoquinoline Molecules within HIV Protein (1AJX) and Its Economic Implication, Elsevier. · DOI
- Xu, 2005, Antibiotic Binding to Monozinc CphA β-Lactamase from Aeromonas hydropila: Quantum Mechanical/Molecular Mechanical and Density Functional Theory Studies, J. Med. Chem., 48, 6679, 10.1021/jm0505112 · doi:10.1021/jm0505112
- Hassan, 2022, Exploring the bioactive sites of new sulfonamide metal chelates for multi-drug resistance: An experimental versus theoretical design, J. Inorg. Organomet. Polym. Mater., 32, 513, 10.1007/s10904-021-02135-6 · DOI
- Ode, 2007, Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations, J. Med. Chem., 50, 1768, 10.1021/jm061158i · DOI
- Amusengeri, A., Tata, R.B., and Bishop, Ö.T. (2020). Understanding the pyrimethamine drug resistance mechanism via combined molecular dynamics and dynamic residue network analysis. Molecules, 25. · DOI
- Vanommeslaeghe, 2014, Molecular mechanics, Curr. Pharm. Des., 20, 3281, 10.2174/13816128113199990600 · DOI
- Bekono, B.D., Sona, A.N., Eni, D.B., Owono, L.C., Megnassan, E., and Ntie-Kang, F. (2021). Molecular mechanics approaches for rational drug design: Forcefields and solvation models. Phys. Sci. Rev., 20190128. · doi:10.1515/9783110682045-013
- Yuriev, 2018, Free Energy Methods in Drug Design: Prospects of “Alchemical Perturbation” in Medicinal Chemistry, J. Med. Chem., 61, 638, 10.1021/acs.jmedchem.7b00681 · DOI · Paper page
- Allen, 2004, Introduction to molecular dynamics simulation, Comput. Soft Matter: Synth. Polym. Proteins, 23, 1
- Moroy, 2015, Sampling of conformational ensemble for virtual screening using molecular dynamics simulations and normal mode analysis, Future Med. Chem., 7, 2317, 10.4155/fmc.15.150 · DOI
- Berman, 2000, The protein data bank, Nucleic Acids Res., 28, 235, 10.1093/nar/28.1.235 · DOI · Paper page
- Whittig, 1986, X-ray diffraction techniques, Meth. Soil Anal. Part 1 Phys. Mineral. Meth., 5, 331
- Javier, 2020, Cryo-Electron Microscopy: Moving Beyond X-Ray Crystal Structures for Drug Receptors and Drug Development, Ann. Rev. Pharmacol. Toxicol., 60, 51, 10.1146/annurev-pharmtox-010919-023545 · DOI
- Bai, 2015, How cryo-EM is revolutionizing structural biology, Trends Biochem. Sci., 40, 49, 10.1016/j.tibs.2014.10.005 · DOI · Paper page
- Weissenberger, 2021, Understanding the invisible hands of sample preparation for cryo-EM, Nat. Methods, 18, 463, 10.1038/s41592-021-01130-6 · DOI · Paper page
- Krieger, 2003, Homology modeling, Meth. Biochem. Anal., 44, 509, 10.1002/0471721204.ch25 · DOI · Paper page
- Cavasotto, 2009, Homology modeling in drug discovery: Current trends and applications, Drug Discov. Today, 14, 676, 10.1016/j.drudis.2009.04.006 · DOI · Paper page
- AlQuraishi, 2019, AlphaFold at CASP13, Bioinformatics, 35, 4862, 10.1093/bioinformatics/btz422 · DOI · Paper page
- MacKerell, A.D. (2001). Atomistic models and force fields. Computational Biochemistry and Biophysics, CRC Press. · doi:10.1201/9780203903827.ch2
- Robertson, 2015, Improved peptide and protein torsional energetics with the OPLS-AA force field, J. Chem. Theory Comput., 11, 3499, 10.1021/acs.jctc.5b00356 · DOI · Paper page
- Senftle, 2016, The ReaxFF reactive force-field: Development, applications and future directions, NPJ Comput. Mater., 2, 15011, 10.1038/npjcompumats.2015.11 · DOI · Paper page
- Hagler, 2019, Biomolecular force fields: Where have we been, where are we now, where do we need to go and how do we get there?, J. Comput. Aided Mol. Des., 33, 133, 10.1007/s10822-018-0111-4 · DOI
- Lee, 2017, Validating a Coarse-Grained Voltage Activation Model by Comparing Its Performance to the Results of Monte Carlo Simulations, J. Phys. Chem. B, 121, 11284, 10.1021/acs.jpcb.7b09530 · DOI
- Vorobyov, 2016, Refining the treatment of membrane proteins by coarse-grained models, Proteins: Struct. Funct. Bioinform., 84, 92, 10.1002/prot.24958 · DOI
- Horikoshi, 2021, Long-range structural defects by pathogenic mutations in most severe glucose-6-phosphate dehydrogenase deficiency, Proc. Natl. Acad. Sci. USA, 118, e2022790118, 10.1073/pnas.2022790118 · DOI
- Budaitis, 2021, Pathogenic mutations in the kinesin-3 motor KIF1A diminish force generation and movement through allosteric mechanisms, J. Cell Biol., 220, e202004227, 10.1083/jcb.202004227 · DOI · Paper page
- Korovesis, 2018, The architecture of EGFR’s basal complexes reveals autoinhibition mechanisms in dimers and oligomers, Nat. Commun., 9, 4325, 10.1038/s41467-018-06632-0 · DOI
- Zhu, M., Wang, D.D., and Yan, H. (2021). Genotype-determined EGFR-RTK heterodimerization and its effects on drug resistance in lung Cancer treatment revealed by molecular dynamics simulations. BMC Mol. Cell Biol., 22. · DOI
- Tyni, 2018, Natural polyphenols as sirtuin 6 modulators, Sci. Rep., 8, 4163, 10.1038/s41598-018-22388-5 · DOI · Paper page
- Jiang, 2022, An Intelligent Strategy with All-Atom Molecular Dynamics Simulations for the Design of Lipopeptides against Multidrug-Resistant Pseudomonas aeruginosa, J. Med. Chem., 65, 10001, 10.1021/acs.jmedchem.2c00657 · DOI
- Cavasotto, 2007, Ligand docking and structure-based virtual screening in drug discovery, Curr. Top. Med. Chem., 7, 1006, 10.2174/156802607780906753 · DOI · Paper page
- Kitchen, 2004, Docking and scoring in virtual screening for drug discovery: Methods and applications, Nat. Rev. Drug Discov., 3, 935, 10.1038/nrd1549 · DOI · Paper page
- Shoichet, 2004, Virtual screening of chemical libraries, Nature, 432, 862, 10.1038/nature03197 · DOI · Paper page
- Keseru, 2011, Integration of virtual and high throughput screening in lead discovery settings, Comb. Chem. High Throughput Screen., 14, 889, 10.2174/138620711797537148 · DOI
- Hu, 2013, Inhibitors of the Yersinia protein tyrosine phosphatase through high throughput and virtual screening approaches, Bioorganic Med. Chem. Lett., 23, 1056, 10.1016/j.bmcl.2012.12.018 · doi:10.1016/j.bmcl.2012.12.018
- Lee, 2014, Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings, Bioorganic Med. Chem., 22, 167, 10.1016/j.bmc.2013.11.041 · DOI
- Cheng, 2012, Structure-based virtual screening for drug discovery: A problem-centric review, AAPS J., 14, 133, 10.1208/s12248-012-9322-0 · DOI · Paper page
- Sastry, 2013, Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments, J. Comput. Aided Mol. Des., 27, 221, 10.1007/s10822-013-9644-8 · DOI · Paper page
- Sliwoski, 2014, Computational methods in drug discovery, Pharmacol. Rev., 66, 334, 10.1124/pr.112.007336 · DOI · Paper page
- Taylor, 2002, A review of protein-small molecule docking methods, J. Comput. Aided Mol. Des., 16, 151, 10.1023/A:1020155510718 · DOI · Paper page
- Stahl, 2003, Binding site characteristics in structure-based virtual screening: Evaluation of current docking tools, J. Mol. Model., 9, 47, 10.1007/s00894-002-0112-y · DOI · Paper page
- Cross, 2009, Comparison of several molecular docking programs: Pose prediction and virtual screening accuracy, J. Chem. Inf. Model., 49, 1455, 10.1021/ci900056c · DOI · Paper page
- Kumar, 2021, In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19, VirusDisease, 32, 29, 10.1007/s13337-020-00643-6 · DOI
- Pantsar, T., and Poso, A. (2018). Binding affinity via docking: Fact and fiction. Molecules, 23. · DOI · Paper page
- Macip, 2022, Haste makes waste: A critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition, Med. Res. Rev., 42, 744, 10.1002/med.21862 · DOI
- Murugan, N.A., Podobas, A., Gadioli, D., Vitali, E., Palermo, G., and Markidis, S. (2022). A review on parallel virtual screening softwares for high-performance computers. Pharmaceuticals, 15. · DOI
- Rastelli, 2019, Refinement and Rescoring of Virtual Screening Results, Front. Chem., 7, 498, 10.3389/fchem.2019.00498 · DOI
- Salmaso, 2018, Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overview, Front. Pharmacol., 9, 923, 10.3389/fphar.2018.00923 · DOI · Paper page
- Liu, W., Schmidt, B., Voss, G., and Müller-Wittig, W. (2007, January 18–21). Molecular dynamics simulations on commodity GPUs with CUDA. Proceedings of the International Conference on High-Performance Computing, Goa, India.
- Ramalingam, 1996, On the computational complexity of dynamic graph problems, Theor. Comput. Sci., 158, 233, 10.1016/0304-3975(95)00079-8 · DOI
- Gotz, 2013, Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald, J. Chem. Theory Comput., 9, 3878, 10.1021/ct400314y · DOI · Paper page
- Genheden, 2015, The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities, Expert Opin. Drug Discov., 10, 449, 10.1517/17460441.2015.1032936 · DOI · Paper page
- Ahmad, 2021, Optimizing Bedaquiline for cardiotoxicity by structure based virtual screening, DFT analysis and molecular dynamic simulation studies to identify selective MDR-TB inhibitors, Silico Pharmacol., 9, 23, 10.1007/s40203-021-00086-x · DOI
- Castillo, 2019, In silico hit optimization toward AKT inhibition: Fragment-based approach, molecular docking and molecular dynamics study, J. Biomol. Struct. Dyn., 37, 4301, 10.1080/07391102.2018.1546618 · doi:10.1080/07391102.2018.1546618
- Zhang, 2017, Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay, J. Chem. Inf. Model., 57, 355, 10.1021/acs.jcim.6b00551 · DOI
- Ruskamo, 2014, Atomic resolution view into the structure–function relationships of the human myelin peripheral membrane protein P2, Acta Crystallogr. Sect. D: Biol.Crystallogr., 70, 165, 10.1107/S1399004713027910 · DOI · Paper page
- Kmiecik, 2016, Coarse-grained protein models and their applications, Chem. Rev., 116, 7898, 10.1021/acs.chemrev.6b00163 · DOI · Paper page
- Singh, N., and Li, W. (2019). Recent advances in coarse-grained models for biomolecules and their applications. Int. J. Mol. Sci., 20. · DOI
- Vicatos, 2014, An effective Coarse-grained model for biological simulations: Recent refinements and validations, Proteins: Struct. Funct. Bioinform., 82, 1168, 10.1002/prot.24482 · DOI
- Bai, 2021, Predicting Mutational Effects on Receptor Binding of the Spike Protein of SARS-CoV-2 Variants, J. Am. Chem. Soc., 143, 17646, 10.1021/jacs.1c07965 · DOI
- Bai, 2021, Exploring the Activation Process of the β2AR-Gs Complex, J. Am. Chem. Soc., 143, 11044, 10.1021/jacs.1c03696 · DOI
- Mukherjee, 2011, Electrostatic origin of the mechanochemical rotary mechanism and the catalytic dwell of F1-ATPase, Proc. Natl. Acad. Sci. USA, 108, 20550, 10.1073/pnas.1117024108 · DOI
- Bai, 2019, Revisiting the protomotive vectorial motion of F0-ATPase, Proc. Natl. Acad. Sci. USA, 116, 19484, 10.1073/pnas.1909032116 · doi:10.1073/pnas.1909032116
- Zhang, 2012, Dissecting the kinematics of the kinesin step, Structure, 20, 628, 10.1016/j.str.2012.02.013 · DOI
- Warshel, 2006, Modeling electrostatic effects in proteins, Biochim. Biophys. Acta Proteins Proteom., 1764, 1647, 10.1016/j.bbapap.2006.08.007 · DOI · Paper page
- Marrone, 1997, Structure-based drug design: Computational advances, Annu. Rev. Pharmacol. Toxicol., 37, 71, 10.1146/annurev.pharmtox.37.1.71 · DOI
- Raha, 2007, The role of quantum mechanics in structure-based drug design, Drug Discov. Today, 12, 725, 10.1016/j.drudis.2007.07.006 · DOI · Paper page
- Enyedy, 2008, Can we use docking and scoring for hit-to-lead optimization?, J. Comput. Aided Mol. Des., 22, 161, 10.1007/s10822-007-9165-4 · DOI
- Guterres, 2020, Improving protein-ligand docking results with high-throughput molecular dynamics simulations, J. Chem. Inf. Model., 60, 2189, 10.1021/acs.jcim.0c00057 · DOI · Paper page
- Berishvili, V., Kuimov, A., Voronkov, A., Radchenko, E., Kumar, P., Choonara, Y., Pillay, V., Kamal, A., and Palyulin, V. (2020). Discovery of novel tankyrase inhibitors through molecular docking-based virtual screening and molecular dynamics simulation studies. Molecules, 25. · DOI
- Halgren, 2001, Polarizable force fields, Curr. Opin. Struct. Biol., 11, 236, 10.1016/S0959-440X(00)00196-2 · DOI · Paper page
- Arodola, 2017, Quantum mechanics implementation in drug-design workflows: Does it really help?, Drug Des. Dev. Ther., 11, 2551, 10.2147/DDDT.S126344 · DOI
- Ribeiro, 2015, Enzymatic flexibility and reaction rate: A QM/MM study of HIV-1 protease, ACS Catal., 5, 5617, 10.1021/acscatal.5b00759 · DOI
- Uddin, 2019, Halogenated derivatives of methotrexate as human dihydrofolate reductase inhibitors in cancer chemotherapy, J. Biomol. Struct. Dyn., 38, 901, 10.1080/07391102.2019.1591302 · DOI
- Nakliang, P., Lazim, R., Chang, H., and Choi, S. (2020). Multiscale molecular modeling in G protein-coupled receptor (GPCR)-ligand studies. Biomolecules, 10. · DOI
- Zhou, 2010, Catalytic reaction mechanism of acetylcholinesterase determined by Born-Oppenheimer ab initio QM/MM molecular dynamics simulations, J. Phys. Chem. B, 114, 8817, 10.1021/jp104258d · DOI · Paper page
- Chen, 2011, Reaction pathway and free energy profile for butyrylcholinesterase-catalyzed hydrolysis of acetylcholine, J. Phys. Chem. B, 115, 1315, 10.1021/jp110709a · doi:10.1021/jp110709a
- Cheng, 2007, Acetylcholinesterase: Mechanisms of covalent inhibition of wild-type and H447I mutant determined by computational analyses, J. Am. Chem. Soc., 129, 6562, 10.1021/ja070601r · DOI
- Liu, 2009, Reaction pathway and free-energy barrier for reactivation of dimethylphosphoryl-inhibited human acetylcholinesterase, J. Phys. Chem. B, 113, 16226, 10.1021/jp9055335 · DOI
- Olivieri, L., and Gardebien, F. (2014). Structure-affinity properties of a high-affinity ligand of FKBP12 studied by molecular simulations of a binding intermediate. PLoS ONE, 9. · doi:10.1371/journal.pone.0114610
- Tosso, 2013, Molecular modeling study of dihydrofolate reductase inhibitors. Molecular dynamics simulations, quantum mechanical calculations, and experimental corroboration, J. Chem. Inf. Model., 53, 2018, 10.1021/ci400178h · DOI
- Cho, 2005, Importance of accurate charges in molecular docking: Quantum mechanical/molecular mechanical (QM/MM) approach, J. Comput. Chem., 26, 915, 10.1002/jcc.20222 · DOI · Paper page
- Raha, 2005, Large-scale validation of a quantum mechanics based scoring function: Predicting the binding affinity and the binding mode of a diverse set of protein-ligand complexes, J. Med. Chem., 48, 4558, 10.1021/jm048973n · DOI · Paper page
- Gleeson, 2009, QM/MM calculations in drug discovery: A useful method for studying binding phenomena?, J. Chem. Inf. Model., 49, 670, 10.1021/ci800419j · DOI
- Zhang, 2012, Recent development in quantum mechanics/molecular mechanics modeling for materials, Int. J. Multiscale Comput. Eng., 10, 65
- Cavasotto, 2018, Quantum chemical approaches in structure-based virtual screening and lead optimization, Front. Chem., 6, 188, 10.3389/fchem.2018.00188 · DOI
- Fong, 2009, Assessment of QM/MM scoring functions for molecular docking to HIV-1 protease, J. Chem. Inf. Model., 49, 913, 10.1021/ci800432s · DOI
- Kim, 2016, Incorporating QM and solvation into docking for applications to GPCR targets, Phys. Chem. Chem. Phys., 18, 28281, 10.1039/C6CP04742D · DOI
- Latorre, 2004, Universality of entanglement and quantum-computation complexity, Phys. Rev. A, 69, 052308, 10.1103/PhysRevA.69.052308 · DOI · Paper page
- Senn, 2009, QM/MM methods for biomolecular systems, Angew. Chem. Int. Ed., 48, 1198, 10.1002/anie.200802019 · DOI · Paper page
- Wilson, E., Vant, J., Layton, J., Boyd, R., Lee, H., Turilli, M., Hernández, B., Wilkinson, S., Jha, S., and Gupta, C. (2021). Large-Scale Molecular Dynamics Simulations of Cellular Compartments. Structure and Function of Membrane Proteins, Springer. · DOI
- Hoque, 2017, An approach of computer-aided drug design (CADD) tools for in silico pharmaceutical drug design and development, Int. J. Adv. Res. Biol. Sci., 4, 60, 10.22192/ijarbs.2017.04.02.009 · DOI
- McKenna, 1983, Captopril, Br. Med. J., 287, 1299, 10.1136/bmj.287.6401.1299 · doi:10.1136/bmj.287.6401.1299
- 2021, Drug repurposing: A strategy for discovering inhibitors against emerging viral infections, Curr. Med. Chem., 28, 2887, 10.2174/0929867327666200812215852 · DOI
- Huang, 2010, Current developments of computer-aided drug design, J. Taiwan Instit. Chem. Eng., 41, 623, 10.1016/j.jtice.2010.03.017 · DOI
- Druker, 2000, Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia, J. Clin. Investig., 105, 3, 10.1172/JCI9083 · DOI · Paper page
- 2007, Computer-aided drug design: The next 20 years, J. Comput. Aided Mol. Des., 21, 591, 10.1007/s10822-007-9142-y · DOI · Paper page
- Gervasio, 2018, From computers to bedside: Computational chemistry contributing to FDA approval, Biomolecular Simulations in Structure-Based Drug Discover, Volume 75, 163
- Macalino, S.J.Y., Basith, S., Clavio, N.A.B., Chang, H., Kang, S., and Choi, S. (2018). Evolution of in silico strategies for protein-protein interaction drug discovery. Molecules, 23. · DOI
- Wang, 2018, Structure-based drug design strategies and challenges, Curr. Top. Med. Chem., 18, 998, 10.2174/1568026618666180813152921 · DOI
- Lerner, 2021, FRET-based dynamic structural biology: Challenges, perspectives and an appeal for open-science practices, Elife, 10, e60416, 10.7554/eLife.60416 · DOI · Paper page
- Lee, J., Freddolino, P.L., and Zhang, Y. (2017). Ab initio protein structure prediction. From Protein Structure to Function with Bioinformatics, Springer. · DOI
- Pan, 2017, Identification of the tolfenamic acid binding pocket in PrbP from Liberibacter asiaticus, Front. Microbiol., 8, 1591, 10.3389/fmicb.2017.01591 · DOI
- 2006, Blind docking of drug-sized compounds to proteins with up to a thousand residues, FEBS Lett., 580, 1447, 10.1016/j.febslet.2006.01.074 · DOI · Paper page
- Hassan, 2017, Protein-ligand blind docking using QuickVina-W with inter-process spatio-temporal integration, Sci. Rep., 7, 15451, 10.1038/s41598-017-15571-7 · DOI · Paper page
- Liu, 2020, CB-Dock: A web server for cavity detection-guided protein-ligand blind docking, Acta Pharmacol. Sin., 41, 138, 10.1038/s41401-019-0228-6 · DOI · Paper page
- 2002, Efficient docking of peptides to proteins without prior knowledge of the binding site, Protein Sci., 11, 1729, 10.1110/ps.0202302 · DOI · Paper page
- Iorga, 2006, Acetylcholine nicotinic receptors: Finding the putative binding site of allosteric modulators using the “blind docking” approach, J. Mol. Model., 12, 366, 10.1007/s00894-005-0057-z · DOI
- Liang, 2020, Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface, Comput. Biol. Chem., 89, 107372, 10.1016/j.compbiolchem.2020.107372 · DOI
- Doerr, 2017, DeepSite: Protein-binding site predictor using 3D-convolutional neural networks, Bioinformatics, 33, 3036, 10.1093/bioinformatics/btx350 · DOI · Paper page
- Volkamer, 2012, Combining global and local measures for structure-based druggability predictions, J. Chem. Inf. Model., 52, 360, 10.1021/ci200454v · DOI · Paper page
- Yu, 2010, Roll: A new algorithm for the detection of protein pockets and cavities with a rolling probe sphere, Bioinformatics, 26, 46, 10.1093/bioinformatics/btp599 · DOI · Paper page
- Schmidtke, 2010, Fpocket: Online tools for protein ensemble pocket detection and tracking, Nucleic Acids Res., 38, W582, 10.1093/nar/gkq383 · DOI · Paper page
- Bruno, 2016, The chemosensitizing agent lubeluzole binds calmodulin and inhibits Ca2+/calmodulin-dependent kinase II, Eur. J. Med. Chem., 116, 36, 10.1016/j.ejmech.2016.03.045 · DOI
- Wang, 2016, RaptorX-Property: A web server for protein structure property prediction, Nucleic Acids Res., 44, W430, 10.1093/nar/gkw306 · DOI · Paper page
- Yang, 2013, Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment, Bioinformatics, 29, 2588, 10.1093/bioinformatics/btt447 · DOI · Paper page
- Kalidas, 2008, PocketDepth: A new depth based algorithm for identification of ligand binding sites in proteins, J. Struct. Biol., 161, 31, 10.1016/j.jsb.2007.09.005 · DOI
- Gorgulla, 2020, An open-source drug discovery platform enables ultra-large virtual screens, Nature, 580, 663, 10.1038/s41586-020-2117-z · DOI · Paper page
- Irwin, 2012, ZINC: A free tool to discover chemistry for biology, J. Chem. Inf. Model, 52, 1757, 10.1021/ci3001277 · DOI · Paper page
- Kiss, 2012, http://Mcule.com: A public web service for drug discovery, J. Cheminform., 4, P17, 10.1186/1758-2946-4-S1-P17 · DOI · Paper page
- Kim, 2019, PubChem 2019 update: Improved access to chemical data, Nucleic Acids Res., 47, D1102, 10.1093/nar/gky1033 · DOI · Paper page
- Wishart, 2008, DrugBank: A knowledgebase for drugs, drug actions and drug targets, Nucleic Acids Res., 36, D901, 10.1093/nar/gkm958 · DOI · Paper page
- Gaulton, 2017, The ChEMBL database in 2017, Nucleic Acids Res., 45, D945, 10.1093/nar/gkw1074 · DOI · Paper page
- Chen, 2005, ChemDB: A public database of small molecules and related chemoinformatics resources, Bioinformatics, 21, 4133, 10.1093/bioinformatics/bti683 · DOI · Paper page
- Lipinski, 2004, Lead- and drug-like compounds: The rule-of-five revolution, Drug Discov. Today: Technol., 1, 337, 10.1016/j.ddtec.2004.11.007 · DOI · Paper page
- Whitty, 2016, Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs, Drug Discov. Today, 21, 712, 10.1016/j.drudis.2016.02.005 · DOI · Paper page
- Huang, 2010, Advances and challenges in protein-ligand docking, Int. J. Mol. Sci., 11, 3016, 10.3390/ijms11083016 · DOI · Paper page
- Morris, 2009, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J. Comput. Chem., 30, 2785, 10.1002/jcc.21256 · DOI · Paper page
- Wu, 2003, Detailed analysis of grid-based molecular docking: A case study of CDOCKER—A CHARMm-based MD docking algorithm, J. Comput. Chem., 24, 1549, 10.1002/jcc.10306 · DOI · Paper page
- Allen, 2015, DOCK 6: Impact of new features and current docking performance, J. Comput. Chem., 36, 1132, 10.1002/jcc.23905 · DOI · Paper page
- Kramer, 1999, Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking, Proteins: Struct. Funct. Bioinform., 37, 228, 10.1002/(SICI)1097-0134(19991101)37:2<228::AID-PROT8>3.0.CO;2-8 · DOI · Paper page
- Berry, 2015, Practical considerations in virtual screening and molecular docking, Emerg. Trends Comput. Biol. Bioinform. Syst. Biol., 1762, 487
- Yadava, 2018, Search algorithms and scoring methods in protein-ligand docking, Endocrinol. Metab. Int. J., 6, 359, 10.15406/emij.2018.06.00212 · DOI
- Hart, 1992, A multiple-start Monte Carlo docking method, Proteins: Struct. Funct. Bioinform., 13, 206, 10.1002/prot.340130304 · DOI · Paper page
- Oshiro, 1995, Flexible ligand docking using a genetic algorithm, J. Comput. Aided Mol. Des., 9, 113, 10.1007/BF00124402 · DOI · Paper page
- Li, 2019, An overview of scoring functions used for protein–ligand interactions in molecular docking, Interdiscip. Sci.: Comput. Life Sci., 11, 320, 10.1007/s12539-019-00327-w · DOI · Paper page
- Stärk, H., Ganea, O., Pattanaik, L., Barzilay, R., and Jaakkola, T. (2022, January 17–23). Equibind: Geometric deep learning for drug binding structure prediction. Proceedings of the International Conference on Machine Learning, Baltimore, MD, USA.
- McNutt, 2021, GNINA 1.0: Molecular docking with deep learning, J. Cheminformatics, 13, 43, 10.1186/s13321-021-00522-2 · DOI · Paper page
- Corso, G., Stärk, H., Jing, B., Barzilay, R., and Jaakkola, T. (2022). DiffDock: Diffusion Steps, Twists, and Turns for Molecular Docking. arXiv.
- Salsbury, 2010, Molecular dynamics simulations of protein dynamics and their relevance to drug discovery, Curr. Opin. Pharmacol., 10, 738, 10.1016/j.coph.2010.09.016 · DOI · Paper page
- Ferreira, 2015, Molecular docking and structure-based drug design strategies, Molecules, 20, 13384, 10.3390/molecules200713384 · DOI · Paper page
- Caflisch, 2018, Protein structure-based drug design: From docking to molecular dynamics, Curr. Opin. Struct. Biol., 48, 93, 10.1016/j.sbi.2017.10.010 · DOI · Paper page
- Philip, 2007, Computer-aided drug design: Integration of structure-based and ligand-based approaches in drug design, Curr. Comput. Aided Drug Des., 3, 133, 10.2174/157340907780809516 · DOI
- Schaller, 2020, Next generation 3D pharmacophore modeling, Wiley Interdiscip. Rev.: Comput. Mol. Sci., 10, e1468
- 2013, Generation of three-dimensional pharmacophore models, Wiley Interdiscip. Rev.: Comput. Mol. Sci., 3, 449
- Yang, 2010, Pharmacophore modeling and applications in drug discovery: Challenges and recent advances, Drug Discov. Today, 15, 444, 10.1016/j.drudis.2010.03.013 · DOI · Paper page
- Barnum, 1996, Identification of common functional configurations among molecules, J. Chem. Inf. Comput. Sci., 36, 563, 10.1021/ci950273r · DOI · Paper page
- Wolber, 2005, LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters, J. Chem. Inf. Model., 45, 160, 10.1021/ci049885e · DOI · Paper page
- Chen, 2008, Conformational sampling of druglike molecules with MOE and catalyst: Implications for pharmacophore modeling and virtual screening, J. Chem. Inf. Model., 48, 1773, 10.1021/ci800130k · DOI
- Liu, 2010, PharmMapper server: A web server for potential drug target identification using pharmacophore mapping approach, Nucleic Acids Res., 38, W609, 10.1093/nar/gkq300 · DOI · Paper page
- Dror, 2008, PharmaGist: A webserver for ligand-based pharmacophore detection, Nucleic Acids Res., 36, W223, 10.1093/nar/gkn187 · doi:10.1093/nar/gkn187
- Dixon, 2006, PHASE: A novel approach to pharmacophore modeling and 3D database searching, Chem. Biol. Drug Des., 67, 370, 10.1111/j.1747-0285.2006.00384.x · DOI · Paper page
- Mallik, 2005, Development of a quasi-dynamic pharmacophore model for anti-complement peptide analogues, J. Am. Chem. Soc., 127, 10967, 10.1021/ja051004c · doi:10.1021/ja051004c
200 of 295 shown
Cited by
AI-Driven Drug Discovery: A Comprehensive Review
Ferreira, F. J. N., & Carneiro, A. S. (2025) · ACS Omega · doi:10.1021/acsomega.5c00549 · Cited by 202
Al Hadithy, Z. A., Al Lawati, A., Al-Zadjali, R., & Al Sinawi, H. (2023) · Cureus · doi:10.7759/cureus.44887 · Cited by 55
Alwadani, F., Lone, A., Hakami, M., Moria, A., Alamer, W., Alghirash, R., Alnawah, A., & Hadadi, A. (2024) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s455260 · Cited by 30
Integrating Computational Design and Experimental Approaches for Next-Generation Biologics
Son, A., Park, J., Kim, W., Lee, W., Yoon, Y., Ji, J., & Kim, H. (2024) · Biomolecules · doi:10.3390/biom14091073 · Cited by 29
Lesovoy, D., Roshchin, K., Sala, B. M., Sandalova, T., Achour, A., Agback, T., Orekhov, V., & Agback, P. (2025) · doi:10.1101/2025.02.07.637034 · Cited by 6
Metadata
- Authors
- Zhang, Y., Luo, M., Wu, P., Wu, S., Lee, T.-Y., & Bai, C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-11-05
- Volume
- 23
- Issue
- 21
- Pages
- 13568
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4308510076
- Cited by
- 150
- References
- 34
- FWCI
- 14.82
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Natural Science Foundation of Youth Fund Project (22103066, 20210316202830001, C10120180043)
- 2021 Basic Research General Project of Shenzhen, China (22103066, 20210316202830001, C10120180043)
- Warshel Institute for Computational Biology at the Chinese University of Hong Kong, Shenzhen (22103066, 20210316202830001, C10120180043)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.